ea0049ep958 | Pituitary - Clinical | ECE2017
Rizvi Ali
, McAdams Brooke
Aim: To describe 2 cases of immune-mediated hypophysitis due to the therapeutic use of Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA4)-blocking antibody.Case 1: A 62 year-old male with history of metastatic melanoma was started on Ipilimumab. After finishing the 4th at 2 months he complained of weakness, fatigue, and fever, prescribed ciprofloxacin and prednisone 20 mg daily, and felt better. 2 days later he was hospitalized with weakness, BP 86/6...